Overview

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2019-05-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-56021927 in Japanese participants with metastatic castration-resistant prostate cancer (mCRPC- prostate cancer that is resistant to medical [for example. hormonal] or surgical treatments).
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Androgens